For patients, this development could mean freedom from regular needle injections into the eye — currently the only FDA-approved treatment option. Beyond reducing discomfort and potential ...
Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...
Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...
The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...
The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...
Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...
Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...